Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy

COVID-19, the novel coronavirus pandemic, has already spread around the globe affecting more than 18 million people. As previously observed with other coronaviruses, SARS-CoV-2 deeply dysregulate the immune system eliciting respiratory failure and a state of systemic hyperinflammation in severely il...

Full description

Saved in:

Bibliographic Details
Published in:	Respiratory medicine Vol. 175; p. 106204
Main Authors:	Torre, Alessandro, Aliberti, Stefano, Castellotti, Paola Francesca, Cirillo, Daniela Maria, Grisolia, Antonella, Mangioni, Davide, Marchetti, Giulia, Rossotti, Roberto, Santus, Pierachille, Besozzi, Giorgio, Villa, Simone, Codecasa, Luigi Ruffo
Format:	Journal Article
Language:	English
Published:	England 01.12.2020
Subjects:	Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use COVID-19 - diagnosis COVID-19 - epidemiology COVID-19 - therapy COVID-19 - virology Female Humans Immunity - physiology Immunosuppression - methods Interferon-gamma Release Tests - methods Interferon-gamma Release Tests - statistics & numerical data Interleukin 1 Receptor Antagonist Protein - therapeutic use Italy - epidemiology Latent Tuberculosis - diagnosis Latent Tuberculosis - epidemiology Latent Tuberculosis - immunology Latent Tuberculosis - prevention & control Lymphopenia - immunology Male Retrospective Studies SARS-CoV-2 - genetics Severity of Illness Index Italy COVID-19 Tuberculosis Tocilizumab Anakinra Cytokine-blocking agents IGRA
ISSN:	1532-3064, 1532-3064
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!